Peer-reviewed veterinary case report
Comparing two trilostane dosing methods for dogs with pituitary
By Braun, C et al.·Published in Schweizer Archiv fur Tierheilkunde·2013·Clinic for Small Animal Internal Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of dogs with pituitary-dependent hyperadrenocorticism (a condition causing excess cortisol) were treated with trilostane, a medication that helps manage this issue. One group received a fixed dose based on their weight, while another group was given a dose based on their individual weight in kilograms. Both groups showed a decrease in cortisol levels and improvement in symptoms, but the second group had fewer side effects and needed fewer adjustments to their medication. Overall, dosing by weight seemed to be a safer and equally effective option for managing this condition in dogs.
People also search for: dog Cushing's disease treatment · trilostane side effects in dogs · how to treat dog hyperadrenocorticism
Abstract
Trilostane is used to treat dogs with pituitary-dependent hyperadrenocorticism (PDH). In our institution, it was initially dosed based on bodyweight (BW) categories, since April 06 it is dosed per kg BW. Our objectives were to compare effectiveness, number of dose adjustments and side effects of the two dose regimens in dogs with PDH. Dogs of group 1 (28 dogs) received trilostane based on BW categories (< 5 kg, 30 mg; 5 - 20 kg, 60 mg and > 20 kg, 120 mg; SID); dogs of group 2 (20 dogs) received 2 - 5 mg/kg SID. Treatment goal was a post-ACTH cortisol of 1 - 2.5 and 1.5 - 5.4 µg/dl in group 1 and 2, respectively. Starting doses were significantly higher in group 1 and stayed higher until re-check at 4 - 7 months. Baseline and post-ACTH cortisol were significantly decreased compared to pre-treatment at all time points in both groups. Significantly more dogs of group 2 (5/20) needed a dose increase at the first re-check and significantly more dogs of group 1 (10/23) a dose reduction at the last re-check. Intermittent discontinuation was necessary in 25 and 10 % of dogs of group 1 and 2, respectively. We conclude that dosing per kg BW results in comparable clinical improvement, decrease in cortisol, but lower risk of side effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24091230/